748 completed, 474 unknown, 293 recruiting, 168 terminated. 1957 Phase 3, 337 Phase 2.
Follow Digestive System Neoplasms: new trials by email Literature Review of Digestive System Neoplasms trials Research Report on Digestive System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 3 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 820 | 2027-06-30 | 2026-09-29 |
| Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation DN022150+AG( Stage I ）, DN022150+AG（Stage II）, placebo+AG（Stage II） - Pancreatic Cancer, Pancreatic Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 465 | 2027-06-06 | 2026-06-18 |
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2027-01-04 | 2026-11-05 |
| Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine - Biliary Tract Cancer (BTC) | Phase 3 | Not yet recruiting | UNICANCER | 990 | 2027-01-02 | 2026-08-04 |
| A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer MRG004A plus best supportive care, Placebo plus best supportive care - Advanced Pancreatic Cancer | Phase 3 | Not yet recruiting | Lepu Biopharma Co., Ltd. | 231 | 2027-01-01 | 2026-05-15 |
| Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma Tislelizumab - Esophageal Cancer | Phase 3 | Not yet recruiting | Asan Medical Center | 172 | 2026-12-31 | 2026-10-29 |
| A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical Resection SYS6010, SG001, SG001 placebo-mimicking - Esophageal Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 585 | 2026-12-30 | 2026-11-09 |
| Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer Apatinib Mesylate Tablets - Gastric Cancer, Surgery | Phase 3 | Not yet recruiting | Fujian Medical University | 118 | 2026-12-25 | 2026-01-02 |
| Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa, Placebo - Colorectal Cancer | Phase 3 | Recruiting | Exelixis | 600 | 2026-12-18 | 2026-11-12 |
| Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma Best Supportive Care (BSC), Personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) - Hepatocellular Carcinoma (HCC) | Phase 3 | Not yet recruiting | University Health Network, Toronto | 60 | 2026-12-01 | 2026-10-26 |
| Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy Radical Gastrectomy with D2 Lymphadenectomy, Standard Systemic Therapy for Advanced Gastric Cancer - Gastric Cancer, Peritoneal Metastasis | Phase 3 | Recruiting | Hua Huang, MD, PhD | 170 | 2026-12-01 | 2026-10-16 |
| Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer Oxaliplatin, 5-Fluorouracil, Capecitabine - Biliary Tract Cancer, Cholangiocarcinoma | Phase 3 | Not yet recruiting | Zhai Wenlong | 90 | 2026-11-30 | 2026-11-04 |
| GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer GFH375 + Cetuximab, Fruquintinib, Trifluridine and Tipiracil - Colorectal Cancer | Phase 3 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 368 | 2026-11-01 | 2026-11-03 |
| A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma SHR-8068 + Adebrelimab + Bevacizumab, SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo, SHR-8068 Placebo + Adebrelimab + Bevacizumab - Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 690 | 2026-11-01 | 2026-10-29 |
| Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC Rilogrotug, Placebo - Cachexia; Cancer, Cachexia | Phase 2 / Phase 3 | Not yet recruiting | AVEO Pharmaceuticals, Inc. | 950 | 2026-11-01 | 2026-10-28 |
| Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer node-sparing modified short-course radiotherapy, standard short-course radiotherapy - Rectal Cancer | Phase 3 | Not yet recruiting | Sir Run Run Shaw Hospital | 210 | 2026-10-25 | 2026-10-28 |
| Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma BGB-B2033, Lenvatinib, Sorafenib - Hepatocellular Carcinoma, Liver Cancer | Phase 3 | Recruiting | BeOne Medicines | 492 | 2026-10-23 | 2026-11-10 |
| Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS short-course radiotherapy, Serplulimab, CapOx(Capecitabine+ Oxaliplatin) - Locally Advanced Colon Cancer, pMMR | Phase 3 | Not yet recruiting | Fudan University | 480 | 2026-10-15 | 2026-10-16 |
| Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer Modular Robot-Assisted Esophagectomy, Conventional Minimally Invasive Esophagectomy - Esophageal Cancer | Phase 3 | Recruiting | Ruijin Hospital | 160 | 2026-10-15 | 2026-10-22 |
Showing 20 of 1957. Sign in to see all of them.
Colorectal Neoplasms (522) · Carcinoma, Hepatocellular (317) · Stomach Neoplasms (301) · Rectal Neoplasms (245) · Colonic Neoplasms (237) · Pancreatic Neoplasms (216) · Esophageal Neoplasms (133) · Liver Neoplasms (91) · Neoplasm Metastasis (91) · Neoplasms (81) · Esophageal Squamous Cell Carcinoma (80) · Biliary Tract Neoplasms (38) · Gallbladder Neoplasms (38) · Gastrointestinal Neoplasms (38) · Gastrointestinal Stromal Tumors (38)
Digestive System Diseases (1945) · Neoplasms by Site (1909) · Neoplasms (1876) · Gastrointestinal Diseases (1326) · Gastrointestinal Neoplasms (1295) · Intestinal Diseases (809) · Intestinal Neoplasms (800) · Rectal Diseases (681) · Colonic Diseases (663) · Neoplasms by Histologic Type (537) · Neoplasms, Glandular and Epithelial (493) · Carcinoma (457) · Liver Diseases (353) · Adenocarcinoma (349)
Fluorouracil (330) · Oxaliplatin (283) · Leucovorin (242) · Capecitabine (225) · Bevacizumab (143) · Irinotecan (143) · Cisplatin (140) · Gemcitabine (135) · Radiotherapy (79) · Paclitaxel (72) · Folfox protocol (69) · Cetuximab (64) · Drug Therapy (59) · Sorafenib (52) · Docetaxel (46)
Sun Yat-sen University (101) · Fudan University (65) · Hoffmann-La Roche (32) · Merck Sharp & Dohme LLC (32) · National Cancer Institute (NCI) (28) · Alliance for Clinical Trials in Oncology (25) · AstraZeneca (24) · Guangxi Medical University (23) · UNICANCER (19) · Sanofi (18) · Chinese University of Hong Kong (17) · Federation Francophone de Cancerologie Digestive (17) · Assistance Publique - Hôpitaux de Paris (16) · Sixth Affiliated Hospital, Sun Yat-sen University (16) · Tianjin Medical University Cancer Institute and Hospital (16)
China (725) · United States (464) · France (333) · South Korea (279) · Italy (275) · Germany (268) · Canada (245) · United Kingdom (237) · Spain (235) · Japan (200) · Belgium (197) · Taiwan (186) · Australia (175) · Poland (157) · Netherlands (149)
Ming Shi, MD (12) · Norman Wolmark, MD (9) · Aimery de Gramont, MD (5) · Alfredo Falcone, MD (4)
PMID 36306483, PMID 31268130, PMID 33356421, PMID 40341124, PMID 12049862, PMID 30679026, PMID 31378656, PMID 11981766, PMID 21997132, PMID 32085892, PMID 34795131, PMID 37310167, PMID 12540794, PMID 19192962, PMID 26049686, PMID 29627309, PMID 32557715, PMID 33439695, PMID 33538338, PMID 35623069, PMID 36064325, PMID 36606664, PMID 37407274, PMID 38661512, PMID 10207464, PMID 12091661, PMID 18650514, PMID 20718753, PMID 20797891, PMID 21104822, PMID 22070868, PMID 22226517, PMID 22421192, PMID 22895629, PMID 23008301, PMID 23148692, PMID 23599758, PMID 23980077, PMID 24224128, PMID 24371038, PMID 24982463, PMID 25077927, PMID 25223462, PMID 26361969, PMID 26559269, PMID 26805559, PMID 26861604, PMID 27223606, PMID 27266524, PMID 27432930
2023 (30), 2025 (18), 2015 (17), 2018 (16), 2014 (12), 2016 (12), 2017 (12), 2019 (11), U10CA031946 (11), 2009 (9), U10CA180868 (9), 2008 (8), U10CA021115 (7), U10CA032102 (7), U10CA180820 (7)